Biologic injections for asthma treatment
Pro Research Analysisby 
Searched over 200M research papers
Biologic Injections for Asthma: Mechanisms and Approved Agents
Biologic injections are advanced treatments for moderate to severe asthma, especially for patients whose symptoms remain uncontrolled despite standard therapies. These biologics are monoclonal antibodies that target specific inflammatory pathways, such as immunoglobulin E (IgE), interleukin-5 (IL-5), IL-5 receptor, IL-4/IL-13 receptor, and thymic stromal lymphopoietin (TSLP) McGregor2019Mavissakalian2020Nagase2022+3 MORE. Currently approved biologics include omalizumab (anti-IgE), mepolizumab, reslizumab, benralizumab (anti-IL-5/IL-5R), dupilumab (anti-IL-4Rα), and tezepelumab (anti-TSLP) Mavissakalian2020Gyawali2025Kyriakopoulos2024+1 MORE.
Efficacy and Clinical Outcomes of Biologic Injections
Biologic therapies have been shown to significantly reduce asthma exacerbations, hospitalizations, and the need for oral corticosteroids, while improving lung function, asthma control, and quality of life in patients with severe asthma McGregor2019Mavissakalian2020Gyawali2025+3 MORE. These benefits are especially pronounced in patients with type 2 (T2) inflammation, as identified by biomarkers like blood eosinophil count and fractional exhaled nitric oxide (FeNO) Nagase2022Gyawali2025Kyriakopoulos2024+2 MORE. Meta-analyses and real-world studies confirm that biologics have a favorable safety profile and are effective in both adults and children Sheppard2021Gyawali2025Kyriakopoulos2024+1 MORE.
Predictors of Response and Remission with Biologic Therapy
Most patients with severe asthma experience a clinical response to biologic therapy, defined as a significant reduction in exacerbations and/or corticosteroid use . About 19–24% of patients may achieve clinical remission, characterized by no exacerbations, no need for maintenance oral corticosteroids, normalized lung function, and well-controlled symptoms after 12 months of treatment . Predictors of better response and remission include shorter disease duration, lower body mass index (BMI), higher baseline blood eosinophil counts (for anti-IL-5/IL-5R therapies), and higher FeNO (for dupilumab) Nagase2022Hansen2023. However, reliable predictors for omalizumab response are still lacking .
Patient and Physician Preferences for Biologic Injections
Patients and physicians value efficacy and safety most when considering biologic treatments for asthma Yang2022Gelhorn2019. Both groups prefer subcutaneous (SC) injections over intravenous administration, less frequent dosing, and the option for home administration due to convenience Yang2022Gelhorn2019. Barriers to biologic use include cost, insurance coverage, location and time of administration, and administrative burden . Many patients and caregivers express interest in home-based injections, which could improve satisfaction and adherence Sheppard2021Yang2022Gelhorn2019.
Real-World Use, Switching, and Discontinuation
Real-world studies highlight the importance of selecting biologics based on asthma phenotype and biomarkers, as well as the potential for switching between biologics if the initial choice is not effective Nagase2022Gyawali2025Kyriakopoulos2024+1 MORE. There is ongoing research into the long-term outcomes of biologic therapy, including the effects of discontinuation and the possibility of achieving sustained remission off treatment Nagase2022Shah2023Hansen2023.
Conclusion
Biologic injections have transformed the management of severe asthma by providing targeted, effective, and generally safe options for patients who do not respond to conventional therapies. They reduce exacerbations, hospitalizations, and corticosteroid use, and improve lung function and quality of life, especially in patients with T2 inflammation. Patient and physician preferences highlight the importance of efficacy, safety, and convenience, with growing interest in home administration. Ongoing research aims to refine patient selection, optimize switching strategies, and explore the potential for long-term remission.
Sources and full results
Most relevant research papers on this topic